Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis

Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis

Introduction: In the phase 3 ASCEND-4 study, ceritinib exhibited improved progression-free survival (PFS) by Blinded Independent Review Committee (BIRC) assessment versus the standard first-line chemotherapy in patients with advanced ALK-rearranged NSCLC. Here, we assessed the efficacy and safety of...

Full description

Bibliographic Details
Main Authors: Daniel S.W. Tan, BSc, M.B.B.S., MRCP, PhD, Sarayut Geater, MD, Chong-Jen Yu, MD, PhD, Chun-Ming Tsai, MD, Te-Chun Hsia, MD, Jun Chen, MD, PhD, Meng-Chih Lin, MD, You Lu, MD, Virote Sriuranpong, MD, Cheng-Ta Yang, MD, Paramita Sen, PhD, Fabrice Branle, MD, Michael Shi, MD, Yi-Long Wu, MD
Format: Article
Language:English
Published: Elsevier 2021-03-01
Series:JTO Clinical and Research Reports
Subjects:
ASCEND-4
Ceritinib
ALK
NSCLC
Online Access:http://www.sciencedirect.com/science/article/pii/S266636432030182X

Internet

http://www.sciencedirect.com/science/article/pii/S266636432030182X

Similar Items